Table 1 Patient characteristics.
From: Cisterna chyli as an optimal marker of tolvaptan response in severe cirrhotic ascites
Factors | All (n = 172) | Group | p value | |
|---|---|---|---|---|
Pilot set (n = 100) | Validation set (n = 72) | |||
Median diameter of Cisterna chyli (mm) | 4 (2–7) | 4 (2–7) | 4 (2–6) | 0.710 |
Median age (years) | 67 (58–74) | 66 (56–75) | 67 (60–72) | 0.742 |
Difference in body weight (kg) from baseline | − 1.8 (− 4.2–0.1) | − 1.8 (− 4.0 to − 0.1) | − 1.9 (− 4.6–0.2) | 0.684 |
Decrease of 1.5 kg or greater from baseline in body weight | 90 (52.3%) | 53 (53.0%) | 37 (51.4%) | 0.835 |
Anti-HCV ( +) | 63 (36.6%) | 36 (36.0%) | 27 (37.5%) | 0.840 |
Male | 114 (66.2%) | 67 (67.0%) | 47 (65.3%) | 0.814 |
Albumin (g/dL) | 2.7 (2.3–3.0) | 2.7 (2.5–3.0) | 2.7 (2.2–3.0) | 0.511 |
Total bilirubin (mg/dL) | 1.9 (1.0–3.6) | 1.9 (0.9–3.3) | 1.9 (1.1–3.8) | 0.525 |
ALT (U/L) | 29 (20–49) | 28 (20–44) | 31 (21–56) | 0.189 |
Sodium (mEq/L) | 136 (132–139) | 136 (132–139) | 136 (132–139) | 0.908 |
Potassium (mEq/L) | 4.1 (3.7–4.5) | 4.1 (3.7–4.8) | 4.0 (3.7–4.5) | 0.748 |
BUN (mg/dL) | 18 (13–26) | 18 (13–28) | 19 (13–25) | 0.918 |
BUN/Creatinine | 21.2 (16.4–27.1) | 21.2 (16.2–27.1) | 21.2 (16.7–26.8) | 0.858 |
eGFR (%) | 62.8 (46.1–82.0) | 62.1 (47.9–78.6) | 67.8 (43.4–86.2) | 0.729 |
CRP (mg/dL) | 1.19 (0.37–3.29) | 1.22 (0.42–3.53) | 1.09 (0.33–2.87) | 0.572 |
Platelet counts (103/μL) | 110 (69–159) | 107 (67–159) | 118 (73–169) | 0.680 |
Prothrombin time (%) | 58.8 (45.5–71.9) | 60.8 (46.3–74.1) | 56.3 (43.3–71.7) | 0.371 |
Ammonia (μg/dL) | 57 (38–84) | 57 (40–83) | 56 (33–88) | 0.544 |
MELD | 10.7 (5.9–14.3) | 11.6 (6.3–14.2) | 10.8 (5.6–14.8) | 0.558 |
Change in urinary volume (mL) a | 686 (203–1156) | 684 (37–1164) | 700 (339–1012) | 0.552 |
FENa | 0.50 (0.24–1.04) | 0.74 (0.30–1.18) | 0.42 (0.21–0.88) | 0.052 |
Urinary sodium (mmol/L) | 51 (28–77) | 49 (29–79) | 52 (27–74) | 0.430 |
Dose of fulosemide (mg) b | 20 (20–40) | 20 (20–40) | 20 (20–40) | 0.969 |
Dose of spironolactone (mg) c | 50 (25–50) | 50 (25–50) | 50 (25–50) | 0.492 |
Furosemide > 40 mg b | 63 (36.6%) | 37 (37.0%) | 26 (36.1%) | 0.905 |
Spironolactone > 50 mg c | 110 (64.0%) | 68 (68.0%) | 42 (58.3%) | 0.193 |
Esophagogastric varices | 110 (64.0%) | 58 (58.0%) | 52 (72.2%) | 0.076 |
History of HCC treatment | 14 (8.1%) | 8 (8.0%) | 6 (8.3%) | 0.937 |
History of liver transplantation | 18 (10.5%) | 13 (13.0%) | 5 (6.9%) | 0.201 |
Duration of tolvaptan treatment (days) | 82 (34–172) | 75 (32–190) | 102 (34–156) | 0.830 |
